faciai: Then let me summarize reasons for caution
Post# of 30067
Posted On: 09/13/2014 3:47:27 PM
faciai: Then let me summarize reasons for caution once again:
1) Early 2013, the pps spiked up to .19 cents then crashed down again to .03 cents!
2) In the summer of 2013 AMBS experienced a "DTC Chill" where no one could buy our shares for a couple of months! That destroyed our financial credibility!
3) In January of 2014 our pps spiked up to .138 cents in anticipation of a LymPro partnership and up listing in Q2 2014. Gerald's announcement of the "codes" and that we weren't going to partner soon.... put us back in the .07 cent range for months.
4) In June & July of 2014 our pps started from .07 cents and rose to .174 cents during the Conference in Copenhagen before it fell to under .13 cents after not getting all the LymPro data we were hoping for. Later on july 31st the pps rose to .194 cents in hopes of getting that data and when we diddn't get it, the pps crashed from .194 cents to under .10 cents, where it was on September 12th until it closed at .105 cents.
We are not where we all thought AMBS would be in mid September. Management doesn't deserve our worship yet, they are not Amgen! Management still needs to prove they can deliver on their promised milestones. To think AMBS has a lock on incomprehensible success is foolishness. We have to execute to succeed. Many small bio-tech stocks with promise have crashed and burned. Shareholders have every right to hold management accountable for it's performance. I am keeping an eye on things. Do you have a problem with that, facai?
1) Early 2013, the pps spiked up to .19 cents then crashed down again to .03 cents!
2) In the summer of 2013 AMBS experienced a "DTC Chill" where no one could buy our shares for a couple of months! That destroyed our financial credibility!
3) In January of 2014 our pps spiked up to .138 cents in anticipation of a LymPro partnership and up listing in Q2 2014. Gerald's announcement of the "codes" and that we weren't going to partner soon.... put us back in the .07 cent range for months.
4) In June & July of 2014 our pps started from .07 cents and rose to .174 cents during the Conference in Copenhagen before it fell to under .13 cents after not getting all the LymPro data we were hoping for. Later on july 31st the pps rose to .194 cents in hopes of getting that data and when we diddn't get it, the pps crashed from .194 cents to under .10 cents, where it was on September 12th until it closed at .105 cents.
We are not where we all thought AMBS would be in mid September. Management doesn't deserve our worship yet, they are not Amgen! Management still needs to prove they can deliver on their promised milestones. To think AMBS has a lock on incomprehensible success is foolishness. We have to execute to succeed. Many small bio-tech stocks with promise have crashed and burned. Shareholders have every right to hold management accountable for it's performance. I am keeping an eye on things. Do you have a problem with that, facai?
(0)
(0)